革命性前列腺癌治疗:现代治疗中PSMA向治疗
A Ricaurte-Fajardo1, V Marulanda-Corzo2, S Ruder3
1Department of Radiology, Division of Molecular Imaging and Therapeutics, Weill Cornell Medicine, New York, United States; Department of Neurosciences, Division of Neurology, Pontificia Universidad Javeriana, Bogotá, Colombia.
以前列腺特异性膜抗原 (PSMA) 向的放射性核素治疗,包括-177 PSMA-617,为转移性割抵抗性前列腺癌 (mCRPC) 提供了新的希望. 新型药物和个性化方法正在推进治疗疗效和患者选择.
科学领域:
- 在瘤学瘤学.
- 核医学是一种核医学.
- 放射性药物疗法是一种放射性药物疗法.
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 存在重大治疗挑战.
- 前列腺特异性膜抗原 (PSMA) 向疗法已成为一个有前途的治疗方式.
- 传统治疗有局限性,需要新的治疗策略.
研究的目的:
- 为前列腺癌的PSMA向放射性核素治疗提供临床进展的关键概述.
- 检查新兴的组合治疗方法和新型放射性核素的开发.
- 突出个性化剂量测量和预测生物标志物在患者选择中的作用.
主要方法:
- 对涉及PSMA向药物的临床试验和比较研究的审查.
- 对-177 PSMA-617 和动-225 治疗方法的数据分析.
- 对PSMA PET成像和生物标志物鉴定进行患者选择的评估.
主要成果:
- -177 PSMA-617在整体存活率和PSA反应方面显示出显著的益处.
- 新型放射性核酸,如动-225,显示了克服治疗耐药性的潜力.
- 通过PSMA PET成像和生物标志物,改善了患者选择个性化治疗的方法.
结论:
- 针对PSMA的放射性核酸疗法正在重塑mCRPC治疗范式.
- 阿尔法发射剂和组合疗法的进步提供了更多的治疗选择.
- 个性化剂量测量和患者选择对于优化前列腺癌管理结果至关重要.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
